Developing the ability to deliver antibodies to disease-relevant cells will expose diverse previously-untouchable intra-cellular targets. This technology will potentially enhance the possibilities of successful treatments for cancer and other diseases.
The use of antibodies to influence intra-cellular targets will enable benefiting from their superior affinity and specificity over small-molecule drugs which are currently the only available means of entering cells. Higher affinity and specificity may be translated to better efficacy and safety.
The novel delivery platform is based on application of chemistry tools to biological drugs which overcome obstacles that these drugs face on their route to intra-cellular domains.
